RxDoctor Payments Data

Elsa Santellano

Nurse Practitioner · Laredo, TXNPI 1952021545

Payments from drug & device makers

$1,477in general payments, 2019–2025

Across 77 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$327
  • Lilly USA, LLC$324
  • AbbVie$201
  • Boehringer Ingelheim$126
  • Novo Nordisk$78
  • Merck$68
  • plus $354 from 15 others

What the payments were for

  • Food & beverage$1,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,477 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$55,868
TradjentaLinagliptin38$43,816
OzempicSemaglutide31$42,237
FarxigaDapagliflozin Propanediol21$25,392
JanumetSitagliptin Phos/Metformin Hcl19$21,793
MounjaroTirzepatide16$17,041
JanuviaSitagliptin Phosphate15$15,402
MyrbetriqMirabegron14$10,508
VascepaIcosapent Ethyl13$9,505
Repatha SureclickEvolocumab13$9,271
LinzessLinaclotide11$9,024
Tresiba Flextouch U-100Insulin Degludec11$6,366
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,074
BelsomraSuvorexant12$5,810
Novolog FlexpenInsulin Aspart17$2,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$126$99,68490 claims
MerckJanumet, Januvia, Belsomra$68$43,00546 claims
Novo NordiskOzempic$78$42,23731 claims
AstraZenecaFarxiga$21$25,39221 claims
Lilly USA, LLCMounjaro$324$17,04116 claims
AbbVieLinzess$201$9,02411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →